These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6187876)

  • 1. Cancer and the immune system.
    Karakousis CP
    J Med; 1980; 11(5-6):449-58. PubMed ID: 6187876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The flip side of immune surveillance: immune dependency.
    Prehn RT; Prehn LM
    Immunol Rev; 2008 Apr; 222():341-56. PubMed ID: 18364013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary humoral immune response against tumor membrane antigens and foreign antigens by plasma cell tumor bearer mice.
    Bertini M; Marinone C; Giovarelli M; Comoglio PM
    G Batteriol Virol Immunol; 1977; 70(7-12):144-56. PubMed ID: 615743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.
    Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P
    Cancer Immunol Immunother; 2008 Jan; 57(1):19-29. PubMed ID: 17564702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccines for cancer therapy.
    Sprinzl GM; Kacani L; Schrott-Fischer A; Romani N; Thumfart WF
    Cancer Treat Rev; 2001 Aug; 27(4):247-55. PubMed ID: 11545544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
    Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
    Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The present status of immunodiagnosis and immunotherapy of cancer.
    Pasternak G
    Arch Geschwulstforsch; 1981; 51(4):284-93. PubMed ID: 7032448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is immunosuppression at the tumor site mechanism of evasion of a systemic response?
    Karakousis CP; Sharma S; Brooks SP
    J Med; 2003; 34(1-6):3-14. PubMed ID: 17682306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor models to investigate the therapeutic efficiency of immunomodulators.
    Talmadge E; Lenz BF; Collins MS; Uithoven KA; Schneider MA; Adams JS; Pearson JW; Agee WJ; Fox RE; Oldham RK
    Behring Inst Mitt; 1984 May; (74):219-29. PubMed ID: 6477354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.